Daniel Swisher Net Worth

The estimated Net Worth of Daniel N Jr Swisher is at least 4.72 百万$ dollars as of 1 August 2024. Mr. Swisher owns over 150 units of Jazz Pharmaceuticals plc stock worth over 15,770$ and over the last 19 years he sold JAZZ stock worth over 0$. In addition, he makes 4,707,410$ as President、 Chief Operating Officer at Jazz Pharmaceuticals plc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Swisher JAZZ stock SEC Form 4 insiders trading

Daniel has made over 42 trades of the Jazz Pharmaceuticals plc stock since 2006, according to the Form 4 filled with the SEC. Most recently he exercised 150 units of JAZZ stock worth 879$ on 1 August 2024.

The largest trade he's ever made was buying 476,487 units of Jazz Pharmaceuticals plc stock on 30 June 2010 worth over 133,416$. On average, Daniel trades about 7,856 units every 64 days since 2005. As of 1 August 2024 he still owns at least 150 units of Jazz Pharmaceuticals plc stock.

You can see the complete history of Mr. Swisher stock trades at the bottom of the page.

Daniel Swisher biography

Daniel (Dan) N. Swisher Jr. serves as President, Chief Operating Officer of the Company. He was Chief Executive Officer and a member of the board of directors of Sunesis Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel targeted cancer therapeutics in hematologic and solid tumor malignancies. He also served as Chief Business Officer and Chief Financial Officer of Sunesis from 2001 to 2003. Prior to 2001, Mr. Swisher served in various management roles, including Senior Vice President of Sales and Marketing, for ALZA Corporation from 1992 to 2001. He currently serves as Chairman of the board of directors of Cerus Corporation, a biomedical products company focused on the field of blood transfusion safety, and as a member of the board of directors of Corcept Therapeutics Inc., a pharmaceutical company focused on cortisol-modulating therapeutics to address metabolic and other serious medical conditions.

What is the salary of Daniel Swisher?

As the President、 Chief Operating Officer of Jazz Pharmaceuticals plc, the total compensation of Daniel Swisher at Jazz Pharmaceuticals plc is 4,707,410$. There are 1 executives at Jazz Pharmaceuticals plc getting paid more, with Bruce Cozadd having the highest compensation of 14,713,600$.

How old is Daniel Swisher?

Daniel Swisher is 57, he's been the President、 Chief Operating Officer of Jazz Pharmaceuticals plc since 2018. There are 11 older and 16 younger executives at Jazz Pharmaceuticals plc. The oldest executive at Jazz Pharmaceuticals plc is Catherine Sohn, 67, who is the Independent Director.

What's Daniel Swisher's mailing address?

Daniel's mailing address filed with the SEC is C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA, 94065.

Insiders trading at Jazz Pharmaceuticals plc

Over the last 17 years, insiders at Jazz Pharmaceuticals plc have traded over 1,513,676,247$ worth of Jazz Pharmaceuticals plc stock and bought 1,319,315 units worth 25,188,964$ . The most active insiders traders include Michael W Michelson、Patrick G Enright、Jp Iii Llckkr Partners Iii,.... On average, Jazz Pharmaceuticals plc executives and independent directors trade stock every 11 days with the average trade being worth of 5,162,934$. The most recent stock trade was executed by Mary Elizabeth Henderson on 6 September 2024, trading 1,410 units of JAZZ stock currently worth 152,703$.

What does Jazz Pharmaceuticals plc do?

jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni

Complete history of Mr. Swisher stock trades at Cerus、Corcept Therapeutics Inc、Jazz Pharmaceuticals plc、Protagonist Therapeutics Inc、Sunesis Pharmaceuticals Inc

Jazz Pharmaceuticals plc executives and stock owners

Jazz Pharmaceuticals plc executives and other stock owners filed with the SEC include:

• Bruce Cozadd,
  Chairman of the Board, Chief Executive Officer
• Daniel Swisher,
  President, Chief Operating Officer
• Robert Iannone,
  Executive Vice President, Research and Development
• Neena Patil,
  Senior Vice President, General Counsel
• Bruce C. Cozadd,
  Co-Founder, Chairman & CEO
• Daniel N. Swisher Jr.,
  Pres
• Anne O'Riordan,
  Independent Director
• Dr. Robert Iannone M.D.,
  Exec. VP of R&D and Chief Medical Officer
• Renee D. Gala,
  Exec. VP & CFO
• Kim Sablich,
  Exec. VP & GM of North America
• Rick Winningham,
  Independent Director
• Heather McSharry,
  Independent Director
• Peter Gray,
  Independent Director
• Norbert Riedel,
  Independent Director
• Patrick Enright,
  Independent Director
• Catherine Sohn,
  Independent Director
• Elmar Schnee,
  Independent Director
• Seamus Mulligan,
  Independent Director
• Kenneth O'Keefe,
  Independent Director
• Paul Berns,
  Independent Director
• Diane Schrick,
  Senior Director, Investor Relations
• Patricia Carr,
  Vice President, Finance and Principal Accounting Officer
• Samantha Pearce,
  Senior Vice President, Europe and Rest of World
• Finbar Larkin,
  Senior Vice President - Technical Operations
• Kimberly Sablich,
  Executive Vice President, General Manager - North America
• Renee Gala,
  Chief Financial Officer, Executive Vice President
• Neena M. Patil J.D.,
  Chief Legal Officer and Sr. VP of Legal & Corp. Affairs
• Andrea N. Flynn,
  VP & Head of Investor Relations
• Dr. Finbar Larkin Ph.D.,
  Sr. VP of Technical Operations
• Patricia Carr,
  VP of Fin. & Principal Accounting Officer
• Christopher John Tovey,
  Exec. VP, COO and MD of Europe & International
• Paul Treacy,
  SVP, Technical Operations
• Suzanne Sawochka Hooper,
  EVP and General Counsel
• Karen L. Smith,
  Global Head of R&D and CMO
• Karen J Wilson,
  VP of Finance & PAO
• Russell J. Cox,
  SVP, Sales and Marketing
• Iain Mc Gill,
  Head of EUSA Int'l & SVP
• Matthew P. Young,
  SVP & CFO
• Michael Patrick Miller,
  EVP, US Commercial
• Jennifer E. Cook,
  Director
• Mark Douglas Smith,
  Director
• Jp Llckkr Jp Iii Llckkr Iii...,
  
• Bryan C Cressey,
  Director
• Alan Sebulsky,
  Director
• Kathryn E Falberg,
  SVP and CFO
• Paul Egolkin Perryhuth Joha...,
  
• Michael W Michelson,
  Director
• Samuel D Colella,
  Director
• Financial Holdings Iii, Llc...,
  
• Group Holdings L.P.Kkr Grou...,
  
• Matthew K Fust,
  Senior Vice President & CFO
• Jeffrey K Tobias,
  EVP, Research & Dev and CMO
• Fintan Keegan,
  EVP, Technical Operations
• Cressey Equity Partners Inc...,
  
• Mark G. Eller,
  SVP, Research & Clinical Dev.
• James C Momtazee,
  Director
• Jp Iii Llckkr Partners Iii,...,
  
• Fund Holdings L.P.Kkr Jp Ll...,
  
• Michael A. Des Jardin,
  SVP, Product Development
• Nathaniel M Zilkha,
  Director
• Joan Colligan,
  Principal Accounting Officer
• Janne Lt Wissel,
  Senior VP of Development
• James B Tananbaum,
  Director
• Samuel R Saks,
  Chief Executive Officer
• Robert M Myers,
  President
• E Alexander Albert,
  Director
• Jp Llckkr Jp Iii Llckkr Iii...,
  
• Paul Ehuth Johannes Pfisher...,
  
• Michael W Janetschek Willia...,
  
• Carol A Gamble,
  SVP, GC and Corporate Secty
• Management Llcmignone Rober...,
  
• Henry Rroberts George Rgree...,
  
• Michael Wkkr Financial Hold...,
  
• Paul Ehuth Johannes Pfisher...,
  
• Patel Jaimin,
  Director
• Michael Wkkr Financial Hold...,
  
• Kim Sablich,
  EVP, GM of U.S.
• Mary Elizabeth Henderson,
  SVP, Technical Operations
• Christopher J. Tovey,
  EVP, COO & Managing Director E
• Laura Hamill,
  Director
• Patrick Kennedy,
  Director
• Philip L Johnson,
  EVP & Chief Financial Officer